<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03083054</url>
  </required_header>
  <id_info>
    <org_study_id>1.140.423</org_study_id>
    <nct_id>NCT03083054</nct_id>
  </id_info>
  <brief_title>Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia</brief_title>
  <official_title>Cellular Immunotherapy as a Treatment Option for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Campinas, Brazil</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Campinas, Brazil</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this work is to conduct a clinical study for the development and&#xD;
      application of a vaccine with autologous dendritic cells submitted to electroporation with&#xD;
      Wilm's tumor 1 (WT1) messenger ribonucleic acid (mRNA), as an adjuvant treatment of high-risk&#xD;
      Myelodysplastic Syndromes and Acute Myeloid Leukemia, aiming to delay the progression of the&#xD;
      disease or its relapse and increase overall and event-free survival.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">July 2021</completion_date>
  <primary_completion_date type="Actual">July 12, 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High Risk Myelodysplastic Syndromes or Acute Myeloid Leukemia</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Autologous dendritic cells electroporated with WT1 mRNA</intervention_name>
    <description>Production and application of autologous dendritic cells vaccines, 4 doses, biweekly</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals between the ages of 18 and 70&#xD;
&#xD;
          -  High-risk myelodysplasia (AREB 1 or AREB 2 subtypes) and Acute Myeloid Leukemia&#xD;
&#xD;
          -  Minimum interval of 30 days between the last cycle of chemotherapy (when it occurs)&#xD;
             and start of immunotherapy&#xD;
&#xD;
          -  Performance status between 0 and 3 on the WHO (World Health Organization)-ECOG&#xD;
             (Eastern Cooperative Oncology Group) scale&#xD;
&#xD;
          -  Calculated creatinine clearance&gt; 30 ml / min using the Cockcroft-Gault formula&#xD;
&#xD;
          -  Total bilirubin less than or equal to twice the lower limit of the normal range in the&#xD;
             institution and aspartate aminotransferase (AST) less than or equal to twice the upper&#xD;
             limit of normal&#xD;
&#xD;
          -  Absence of blasts in peripheral blood&#xD;
&#xD;
          -  Leukocyte count greater than 3000 cells / mm3, hemoglobin greater than 9.0 g / dl and&#xD;
             platelets greater than 70,000 platelets / mm3, if possible. (If the patient does not&#xD;
             meet these criteria for apheresis, the possibility of transfusion of blood components&#xD;
             after leukapheresis will be proposed and the patient should sign a specific term of&#xD;
             science on the possibility of transfusion)&#xD;
&#xD;
          -  Normal cardiac evaluation&#xD;
&#xD;
          -  Negative serologies for hepatitis B and C viruses and HIV&#xD;
&#xD;
          -  Written informed consent form signed before entering the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Does not meet any of the requirements of the inclusion criteria&#xD;
&#xD;
          -  Low risk myelodysplasia by IPSS (International Prognostic Scoring System) or WPSS (WHO&#xD;
             adapted Prognostic Scoring System) scores&#xD;
&#xD;
          -  Individuals with a history of any previous neoplasia, except those with prolonged&#xD;
             clinical remission (more than 5 years) of non-melanoma skin cancers and cervical&#xD;
             cancer in situ&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
&#xD;
          -  Previous immunotherapy or biological therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Hematology and Transfusion Medicine Center</name>
      <address>
        <city>Campinas</city>
        <state>SÃ£o Paulo</state>
        <zip>13083-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>March 12, 2017</study_first_submitted>
  <study_first_submitted_qc>March 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Campinas, Brazil</investigator_affiliation>
    <investigator_full_name>Bruno Deltreggia Benites</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

